PDCD1 and melanoma: For the melanoma FixVac (BNT111), an intravenously administered liposomal RNA (encoding antigens: NY-ESO-1, tyrosinase, MAGE-A3, and TPTE) vaccine developed by BioNTech, the data from an exploratory interim analysis showed that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediated durable objective responses (NCT02410733) [182].